Bjurlin Richard*
In medication research and development, as well as regulatory evaluation, a better biomarker-based assessment of drug safety is required. Identifying drug safety biomarkers such as genes, proteins, miRNA, and single-nucleotide polymorphisms, on the other hand, remains a significant difficulty. We may now investigate drug activities at the organ and organismal levels thanks to breakthroughs in 'omics' and computational tools such as genomics, transcriptomics, metabolomics, proteomics, systems biology, network biology, and systems pharmacology. To aid biomarker-based drug safety evaluation for drug discovery and development, as well as to inform better regulatory decisions, computational and experimental systems pharmacology methodologies could be used. The current state and progress of systems pharmacology methods to the development of prediction models for drug safety evaluation biomarkers.
